Search
AVXS-301
go.drugbank.com/drugs/DB17943ExperimentalAVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase 1 (SOD1) gene.
Ribuvaptan
go.drugbank.com/drugs/DB20059ExperimentalThe usage of the INN stem '-vaptan' in the name indicates that Ribuvaptan is a vasopressin receptor antagonist. Ribuvaptan has a monoisotopic molecular weight of 595.11 Da.
Fasobegron
go.drugbank.com/drugs/DB20200ExperimentalThe usage of the INN stem '-begron' in the name indicates that Fasobegron is a β3 adrenoreceptor agonists. Fasobegron has a monoisotopic molecular weight of 425.14 Da.
Ruclosporin
go.drugbank.com/drugs/DB21199ExperimentalThe usage of the INN stem '-(clo)sporin' in the name indicates that Ruclosporin is a cyclosporine derivative. Ruclosporin has a monoisotopic molecular weight of 1330.92 Da.
Filapixant
go.drugbank.com/drugs/DB21467ExperimentalThe usage of the INN stem '-pixant' in the name indicates that Filapixant is a purinoreceptor (P2X) antagonist. Filapixant has a monoisotopic molecular weight of 521.17 Da.
Teplinovivint
go.drugbank.com/drugs/DB21475ExperimentalThe usage of the INN stem '-vivint' in the name indicates that Teplinovivint is a Wnt signaling inhibitor. Teplinovivint has a monoisotopic molecular weight of 442.21 Da.
Ipivivint
go.drugbank.com/drugs/DB21479ExperimentalThe usage of the INN stem '-vivint' in the name indicates that Ipivivint is a Wnt signaling inhibitor. Ipivivint has a monoisotopic molecular weight of 464.19 Da.
Vornorexant
go.drugbank.com/drugs/DB21483ExperimentalThe usage of the INN stem '-orexant' in the name indicates that Vornorexant is a orexin receptor antagonist. Vornorexant has a monoisotopic molecular weight of 447.18 Da.
Enuvaptan
go.drugbank.com/drugs/DB21492ExperimentalThe usage of the INN stem '-vaptan' in the name indicates that Enuvaptan is a vasopressin receptor antagonist. Enuvaptan has a monoisotopic molecular weight of 576.09 Da.
Triplizumab
go.drugbank.com/drugs/DB30669Investigationaltriplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized